Q&A session Spotlight on Leading with Tim Lahurque Pfizer to a Templeman International newfuture page 21 page 7 page 24 Contents Retzlaff steps down 9September 2016 Issue Number 468 in Stada shake-up COMPANY NEWS tada’sHartmut Retzlaff has resigned J&J researching skin treatments 3 Sfrom his position as chairman of the man- George to lead Stada Brands 4 agement board at the German company “due Perrigo reviews options 5 to personal circumstances”. Sanofi prepares for6The move came shortly before Stada an- growth in Australia nounced the make-up of its newsupervisory Latin America lifts 8 board following aperiod of instability after minor- turnoveratMerck ity shareholder Active Ownership’sattempts to gain control of the committee (OTC bulletin, Boehringer reports OTCrise 9 27 May 2016, page 6). Amazon Dash enters EU 12 In June, Stada announced that Retzlaffhad taken leave from his role as chief executive officer GENERAL NEWS at the firm “due to aserious, long-term illness” (OTC bulletin,17June 2016, page 27). Hartmut Retzlaff Homoeopathygets 13 Executive board member Matthias Wieden- Following the vote, fivenew members joined trade body support fels has taken overthe chief executive officer the supervisory board, four of which had been FDAissues revised 16 role “until further notice”, along with responsi- nominated by Stada. Only Eric Cornut, Nov- supplement rules bility for corporate strategy and production. artis’ former chief ethics, compliance and poli- ASMI welcomes 17 Joining Stada in 1986 as sales and market- cy officer,was elected from the list of candi- labelling changes ing director for its Stadapharm division, Retz- dates drawn up by Active Ownership. laffbecame head of Stadapharm in 1991. He Joining Cornut on the board are Stada can- MARKETING NEWS stepped up to lead the German group two didates: Rolf Hoffmann, former senior vice- years later,and in September last year,Stada president of US commercial operations at Am- Lanes strengthens Earex in UK 19 extended Retzlaff’semployment contract by gen; Dr Birgit Kudlek, previously chief operat- Regaine adds foam 19 fiveyears until August 2021 (OTC bulletin, ing officer at Aenova;Tina Müller,chief mar- in Germany 25 September 2015, page 23). keting officer at car manufacturer Opel; and Awards reflect digital growth 22 Shortly after Retzlaffstepped down, Stada Dr Gunnar Riemann, previously head of En- thwarted attempts by Active Ownership to re- vironmental Science at Bayer Crop Science. REGULARS place the majority of the company’ssupervisory Stada’sCarl Oetker has been elected chair- board with its owncandidates. manofthe supervisory board, replacing Martin Spotlight on –Lahurque 7 Prior to avote at the company’sannual Abend, who wasremovedatthe meeting. Q&A –with Boehringer 21 general meeting, Stada had warned that Active Meanwhile, Stada announced that Dieno Ingelheim’sTim Templeman Ownership’sdesire to replace six supervisory George had been promoted to takecharge of Events –Our regular listing 23 board directors would be a“disruptive action”, the firm’sBranded Products unit as part of a People –Recordati changes 27 as well as “ill-considered and irresponsible” “fundamental change to the firm’sreporting management team (OTC bulletin,12August 2016, page 23). structure” (see page 4). OTC Connect with us on: Twitter LinkedIn OTC-bulletin.com Areyour challenges giving you sleepless nights? Data ignites action. Action powers growth. Growth Delivered starts here. Get beyond information and insight to reveal whatitmeans for your business future. To hear about how we can help you deliver growth, visit www.IRIworldwide.com COMPANY NEWS OTC Licensing Agreements Business Strategy Mundipharma J&J is researching grows in MEA treatments for skin undipharma has broadened its OTC prod- Muct portfolio in the Middle East and Africa ohnson & Johnson (J&J) Consumer has by striking a licensing deal with Jordan-based Jpartnered with development company Xy- Munir Sukhtian group. crobe Therapeutics to research new treatments Under the terms of the agreement, UK-based for skin conditions. Mundipharma has gained the commercial rights Thepartnership, the US-based firm said, would for 10 years to market Munir Sukhtian’s HiGeen focus on “further understanding applications of consumer healthcare brand in more than 50 coun- Xycrobe’s platform technology developed for J&J will work with Xycrobe Therapeutics tries across the Middle East and Africa. the treatment of inflammatory skin diseases”. better solutions,” Hitchcock added. The HiGeen line includes foot creams and “The planned collaboration is intended to “The current paradigm for treating skin con- powders, as well as hand sanitisers and creams. provide both companies with information on how ditions, such as acne, completely disregards “The HiGeen range complements very well Xycrobe’s technology may be best applied to the importance of the commensal skin flora,” our consumer health portfolio, which includes future therapeutic and commercial applications,” Hitchcock argued. our Betadine range,” commented Raman Singh, J&J explained. “Overuse of antibiotics has led to a higher president of Mundipharma in Asia-Pacific, According to California-based Xycrobe, its prevalence of resistant strains of bacteria,” he Latin America, Middle East and Africa. “The platform technology “consists of a library of insisted, “and along with that comes less effi- partnership will also help Mundipharma build commensal [bacterial] strains from the skin cacy of conventional treatments.” on our strong leadership in the sector and help microbiome engineered to grow and secrete bio- “Wefeelthatthekeytobettertreatmentsolu- expand our presence.” therapeutics as needed to help treat an array of tions for skin disease lies in understanding our “Mundipharma’s expertise in emerging mar- skin issues”. body’s interaction with the skin microbiome,” kets,” continued Singh, “will increase access The company says it has developed “several Hitchcock explained, “and how we can leverage to these treatments for millions of people.” strains of commensal skin bacteria that show this information.” Deemah Sukhtian, Munir Sukhtian’s man- potential for the significant reduction of inflam- The partnership was facilitated by J&J In- ging director, claimed the “complementary na- mation, promising potential relief from a num- novation, the firm’s venture capital arm which ture” of HiGeen with Mundipharma’s products ber of ailments including acne, dermatitis, ec- aspires to find “the best science and technology, would “provide a stronger proposition to con- zema and psoriasis”. no matter where it is, to solve the greatest unmet sumers in the area of wound care and prevention Commenting on the partnership, Thomas needs of our time”. of infectious diseases”. Hitchcock, Xycrobe’s chief executive officer, Most recently, the Innovation unit partici- “We are confident that our alliance, leveraging said the company was “thrilled” to collabo- pated in a round of funding for the US-based Mundipharma’s expertise and global network,” rate with J&J Consumer. firm First Aid Shot Therapy (FAST) to help the Sukhtian added, “will enhance access to our inno- “It is our hope that this collaboration can fledgling company expand its portfolio of single- vative products and further improve the quality help expedite getting our therapies into the hands dose liquid OTC medicines (OTC bulletin, 27 of life of consumers.” OTC of physicians and their patients who truly need November 2015, page 4). OTC Editor: Matt Stewart Production Editor: Jenna Meredith Advertising Controller: Debi Minal Contributing Editor: David Wallace Director of Subscriptions: Val Davis Assistant Editor: Tom Gallen Editor-in-Chief: Aidan Fry Group Sales Manager: Rob Coulson Assistant Editor: Marie McEvoy Managing Director: Mike Rice Awards Manager: Natalie Cornwell 9 September 2016 | Number 468 Editorial enquiries: OTC bulletin, Te rms & Conditions: While due care has been taken to ensure the accuracy of 4 Poplar Road, Dorridge, Solihull, These can be viewed in full at www.OTC-bulletin.com. information contained in this publication, the publisher West Midlands B93 8DB, UK. No part of this publication may be copied, reproduced, makes no claim that it is free of error and disclaims any Website: www.OTC-bulletin.com stored in a retrieval system, distributed or transmitted by liability whatsoever for any decisions or actions taken as a result of its contents. Te l: +44 (0)1564 777550 any means, including electronic, mechanical, photocopying Fax: +44 (0)1564 777524 or recording, without the prior written permission of © OTC Publications Ltd. All rights reserved. the publisher, or under the terms and conditions of Email: [email protected] ® a Global Site Licence or of a licence issued by the OTC bulletin is registered as a trademark in the European Community. Advertising enquiries: Copyright Licensing Agency (CLA) in London, UK, or Contact: [email protected] rights bodies in other countries that have reciprocal ISSN 1350-1097. Subscription enquiries: agreements with the CLA. Company registered in England No 2765878. Subscription rates are published at Neither may this publication be exported, distributed www.OTC-bulletin.com/subscribe. or circulated by any means without the prior written Printed by Warwick Printing Company Limited, Contact: [email protected] permission of the publisher. Leamington Spa CV31 1QD, UK. 9 September 2016 OTC bulletin 3 OTC COMPANY NEWS Business Strategy/First-Half Results George to lead Stada Brands ieno George has